Sonnet BioTherapeutics Shares Jump After Janssen Pact For Its Three Product Candidates

by Vandana Singh, Benzinga Editor
October 31, 2022 10:57 AM | 1 min read |
  • Sonnet BioTherapeutics Holdings Inc SONN announced a collaboration agreement with Janssen Biotech Inc, a Johnson & Johnson JNJ unit.
  • In vitro and in vivo efficacy of SON-1010 (IL12-FHAB), SON-1210 (IL12-FHAB-IL15), and SON-1410 (IL18-FHAB-IL12) will be evaluated in combination with certain Janssen proprietary cell therapy assets. 
  • The agreement was facilitated by Johnson & Johnson Innovation.
  • Sonnet shall supply the three referenced compounds for use in head-to-head studies. If successful and subject to provisions of the agreement, Sonnet could seek an expanded collaboration.
  • "This is Sonnet's first head-to-head evaluation of three FHAB-based drug candidates, the results of which will be instructive for expanded oncology indications. A successful evaluation could lead to a potential license agreement", said Pankaj Mohan, Sonnet's Founder and CEO.
  • In September, Sonnet BioTherapeutics said that SB101 and SB102 studies dosed 19 subjects to date, with the early review of safety setting the stage for further dose escalation.
  • Additional safety and cytokine-specific data are expected during the Q4 of 2022.
  • Price Action: SONN shares are up 64.70% at $1.91 on the last check Monday.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: BiotechLarge CapNewsPenny StocksHealth CareContractsMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!